title: Inhibitory effects of diallyl disulfide or aspirin on 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced mammary carcinogenesis in rats.
abstract: Modifying effects of diallyl disulfide (DAD), aspirin or DL-alpha-difluoromethylornithine (DFMO) on 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary carcinogenesis in SD rats were investigated. A total of 166 female rats, 6 weeks old, were divided into 8 groups. They were fed a high fat diet throughout the experiment. Starting at 7 weeks of age, groups 1-4 were given PhIP (85 mg/kg body weight in corn oil) by gavage 8 times in 10 days, and groups 5-8 were given corn oil alone. For the beginning 4 weeks, groups 2 and 5 were given DAD at 200 ppm in diet. Similarly groups 3 and 6, and groups 4 and 7 were given aspirin (400 ppm) and DFMO (400 ppm), respectively. Mammary carcinomas were only recognized in groups 1-4 at the termination (25 weeks after the start of experiment). Multiplicity (mean number/rat) of neoplasms in group 2 (PhIP+DAD, 0.90/rat) and group 3 (PhIP+aspirin, 1.37/rat) was significantly smaller than that in group 1 (PhIP alone, 2.45/ rat) (P < 0.005 and P < 0.05, respectively). These results indicate that dietary intake of DAD or aspirin during the time corresponding to initiation phase has chemopreventive potential on PhIP-induced mammary carcinogenesis in rats.
authors.affiliation: Department of Pathology, Gifu University School of Medicine.
authors.forename: N
authors.initials: N
authors.lastname: Suzui
authors.forename: S
authors.initials: S
authors.lastname: Sugie
authors.forename: K M
authors.initials: KM
authors.lastname: Rahman
authors.forename: M
authors.initials: M
authors.lastname: Ohnishi
authors.forename: N
authors.initials: N
authors.lastname: Yoshimi
authors.forename: K
authors.initials: K
authors.lastname: Wakabayashi
authors.forename: H
authors.initials: H
authors.lastname: Mori
mesh_terms: D000284:Administration, Oral; D000498:Allyl Compounds; D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001241:Aspirin / Q000494:pharmacology / Q000627:therapeutic use*; D002273:Carcinogens / Q000633:toxicity; D003314:Corn Oil / Q000633:toxicity; D004041:Dietary Fats / Q000633:toxicity; D004220:Disulfides / Q000494:pharmacology / Q000627:therapeutic use*; D000518:Eflornithine / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D007093:Imidazoles / Q000633:toxicity; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000517:prevention & control*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D000498:Allyl Compounds; D016588:Anticarcinogenic Agents; D002273:Carcinogens; D004041:Dietary Fats; D004220:Disulfides; D007093:Imidazoles; C028009:diallyl disulfide; D003314:Corn Oil; C049584:2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; D001241:Aspirin; D000518:Eflornithine